Life Science Intelligence

On March 10th, Medtronic announced that it has entered into a definitive agreement to acquire Scientia Vascular, a Salt Lake City-based developer of neurovascular access technologies. The transaction is valued at $550 million, with potential undisclosed earn-out and milestone payments post-acquisition. This marks Medtronic’s second acquisition this year, following its earlier CathWorks deal , and signals a clear focus on strengthening capabilities in high-growth categories. The Scientia Vascular acquisition is not just another deal. It reflects a broader shift toward enabling technologies that improve procedural efficiency and expand patient access in stroke care. In stroke treatment, where every second counts, faster and more reliable access can directly influence patient outcomes. The Numbers Behind Stroke and Neurovascular Devices Growth Stroke remains one of the largest and most pressing challenges in healthcare. In the United States alone, approximately 800,000 strokes occur e...

We are already into the second quarter of the year, which makes this a natural moment to assess where medtech funding stands after Q1 2026. Drawing from data collected through LSI’s Compass AI platform, this analysis provides a high-level look at capital deployment, deal activity, and the broader signals shaping the current fundraising environment. Before diving into the numbers, it is important to clarify the scope. The dataset reflects publicly disclosed rounds, spanning early angel investments through later-stage financings such as Series D and beyond. The focus remains tightly centered on medtech, software as a medical device, and diagnostics, with selective inclusion of adjacent healthtech activity when relevant signals emerge. A Closer Look at Medtech Funding Trends The most immediate takeaway from Q1 2026 is a clear contraction when compared to the same period last year. In Q1 2025, the industry saw $3.60 billion raised across 144 deals. In contrast, Q1 2026 recorded $2.41 ...

M&A activity is off to a strong start in 2026. While several large transactions are drawing attention, we are focusing on a move that could carry long-term implications for the spine market: VB Spine’s agreement to acquire the rights to the xvision Spine System from Augmedics. This is not a routine tuck-in acquisition. It reflects a deliberate strategy aimed at addressing structural challenges that have historically limited growth in spine. Before looking at the data, a quick refresher on the two companies involved. A Newly Formed Leader Meets AR Pioneer VB Spine is currently the largest privately held spine company, despite being less than one year old (at the time of this article’s publication). The company was formed in April 2025 when the Viscogliosi Brothers acquired Stryker’s U.S. spinal implants business, excluding MAKO and Copilot. That transaction immediately created a major player with a broad portfolio, expanding global distribution, and a surgeon-focused approach. A...